Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insiders Unload Shares of TRACON Pharmaceuticals Inc. (TCON), Concho Resources Inc. (CXO), and Willamette Valley Vineyards Inc. (WVVI)

Page 1 of 2

Last week’s turmoil in the stock markets was highlighted by the 469-point drop in the Dow Jones Industrial Average on September 1, which was eventually followed by a two-day appreciation. Statistics say that the recoveries after massive sell-offs outside of recessions are generally strong, but that does not prove to be true yet. The Dow gained slightly over 10 points on September 3, so some corporate insiders might have feared that a broader correction is yet to continue. We have identified three companies that had a large insider selling activity in the last couple of days and we will try to figure out the reasoning behind these transactions. TRACON Pharmaceuticals Inc. (NASDAQ:TCON), Concho Resources Inc. (NYSE:CXO), and Willamette Valley Vineyards Inc. (NASDAQ:WVVI) are the companies we will be discussing in this article. It’s worth remembering that insiders might sell stock for a wide range of reasons unrelated to their companies’ prospects, but the sales amid a market correction might bring some useful insights.

Insider Trading 3

Most investors can’t outperform the stock market by individually picking stocks because stock returns aren’t evenly distributed. A randomly picked stock has only a 35% to 45% chance (depending on the investment horizon) to outperform the market. There are a few exceptions, one of which is when it comes to purchases made by corporate insiders. Academic research has shown that certain acquisitions historically outperformed the market by an average of seven percentage points per year. This effect is more pronounced in small-cap stocks. Another exception is the small-cap stock picks of hedge funds. Our research has shown that the 15 most popular small-cap stocks among hedge funds outperformed the market by nearly a percentage point per month between 1999 and 2012. We have been forward testing the performance of these stock picks since the end of August 2012 and they have returned more than 118% over the ensuing 36 months, outperforming the S&P 500 Index by nearly 61 percentage points (read more details here). The trick is focusing only on the best small-cap stock picks of funds, not their large-cap stock picks which are extensively covered by analysts and followed by almost everybody.

Let’s begin by reviewing the insider activity at TRACON Pharmaceuticals Inc. (NASDAQ:TCON), a clinical-stage biopharmaceutical company that focuses on the development of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Jafco Super V3 Investment Limited Partnership, a large shareholder of TRACON, reported selling 8,000 shares at $10.49 per unit on Thursday, trimming its stake to 1.74 million shares. Jafco has been gradually unloading its stake in the biopharmaceutical company, with 29,300 shares sold on aggregate last week, so the sell-offs are not entirely related to the recent pullback of the stock markets. TRACON’s stock has gained nearly 13% year-to-date, in spite of the poor performance over the last month (the stock lost over 17% during this period). It’s quite evident that the stock is news-driven, so any updates on the company’s product pipeline will surely impact its stock. Therefore, potential investors considering putting money into TRACON should keep a close eye on the news surrounding the company. James E. Flynn’s Deerfield Management, one of the 737 investors tracked by Insider Monkey, owns 485,000 shares of TRACON Pharmaceuticals Inc. (NASDAQ:TCON) as of June 30.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!